Ekstrak Terstandar Secara Kimia Daun Brucea Javanica Merrill

The preparation of Brucea leaves have been done for specific parameters and non specific parameter laboratory worb refers to TheNational Agency of Drug and Food Control Regulation for extract quality control. The result for specific extract parameters were the rendement of extraction is 28%, the values of water- extractive and ethanol-extractive are 11.49% and 9.41%, respectively. The result of determination of the non specific parameters of the extract are; loss on drying is 18.95%, the water content is 15.06%, the total ashes is 16.12%. and the level of ashes not dissolved in acid is 11.14%. The analysis of chemical compound shows that the extract containedflavonoid, tannin, and glycoside. For the quantitative control has been measured the level of totalflavonoid wherethe result is 9.901

Anticancer Activity of Ethanolic Extract of Selaginella Plana Hieron. on T47d Cell Line in Vitro

Selaginella sp belongs to the Selaginellaceae family. It has been used in China and Indonesia as a traditional medicine. It hasseveral medicinal properties including antibacterial, anticardiovascular, and anticancer agent. The aim of the present study was to access the anticancer property of the ethanolic extracts of Selaginella plana Hieron. on T47D breast cancer cell line. The proliferation of T47D cell line was detected by SRB (Sulforhodamine B) assay which was measured at a wavelength of 515 nM. The result showed that the IC50 of the ethanolic extract was determined at 7.03 pg/mL. This significant activity was assumed due to its high total flavonoid content. The totalflavonoid content of the ethanolic extract was 23.04%. Flow cytometry analysis indicated that the extract may undergo the cell death via apoptosis pathway. In conclusion, the ethanolic extract of Selaginella plana Hieron: has considerable activity in inhibiting T47D cell line proliferation

Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework

INTRODUCTION: As new antiretrovirals (ARVs), including long‐acting ARVs for treatment and prevention, are approved and introduced, surveillance during pregnancy must become the safety net for evaluating birth outcomes, especially those that are rare and require large numbers of observations. Historically, drug pharmacovigilance in pregnancy has been limited and fragmented between different data sources, resulting in inadequate data to assess risk. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network and World Health Organization convened a Workshop which reviewed strengths and weaknesses of existing programs and discussed an improved framework to integrate existing safety data sources and promote harmonization and digitalization. DISCUSSION: This paper highlights that although robust sources of safety data and surveillance programs exist, key challenges remain, including unknown denominators, reporting bias, under‐reporting (e.g. in voluntary registries), few data sources from resource‐limited settings (most are in North America and Europe), incomplete or inaccurate data (e.g. within routine medical records). However, recent experiences (e.g. with safety signals) and current innovations (e.g. electronic record use in resource‐limited settings and defining adverse outcomes) provide momentum and building blocks for a new framework for active surveillance of ARV safety in pregnancy. A public health approach should be taken using data from existing sources, including registries of pregnancy ARV exposure and birth defects; observational surveillance and cohort studies; clinical trials; and real‐world databases. Key facilitators are harmonization and standardization of outcomes, sharing of materials and tools, and data linkages between programs. Other key facilitators include the development of guidance to estimate sample size and duration of surveillance, ensuring strategic geographic diversity, bringing partners together to share information and engaging the community of women living with HIV. CONCLUSIONS: Looking ahead, critical steps to safely introduce new ARVs include (1) adopting harmonized standards for measuring adverse maternal, birth and infant outcomes; (2) establishing surveillance centres of excellence in areas with high HIV prevalence with harmonized data collection and optimized electronic health records linking maternal/infant data; and (3) creating targets and evaluation goals for reporting progress on implementation and quality of surveillance in pregnancy. The platform will be leveraged to ensure that appropriate contributions and strategic actions by relevant stakeholders are implemented

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

BLOOM: A 176B-Parameter Open-Access Multilingual Language Model

Large language models (LLMs) have been shown to be able to perform new tasks based on a few demonstrations or natural language instructions. While these capabilities have led to widespread adoption, most LLMs are developed by resource-rich organizations and are frequently kept from the public. As a step towards democratizing this powerful technology, we present BLOOM, a 176B-parameter open-access language model designed and built thanks to a collaboration of hundreds of researchers. BLOOM is a decoder-only Transformer language model that was trained on the ROOTS corpus, a dataset comprising hundreds of sources in 46 natural and 13 programming languages (59 in total). We find that BLOOM achieves competitive performance on a wide variety of benchmarks, with stronger results after undergoing multitask prompted finetuning. To facilitate future research and applications using LLMs, we publicly release our models and code under the Responsible AI License

Acute Toxicity Studies of Brucea Javanica Merril Leaves Extract on Mice

The objective of the study was to evaluate the oral acute toxicity of Brucea javanica Merril extract on both Male and Female DDY-Mice. Brucea javanica leaves have activity as a cytotoxic, anti-diarhhea, etc. Brucea javanica leaves extract was administered orally for first 24 hours at various dose levels (562.5mg/kg bw, 1125 mg/kg bw, 2250 mg/kg bw, and 4500 mg/kg bw) to determine the toxicity effects. The treatment groups were compared to the normal control. Vital organs (liver, heart, lymph, lungs, etc) and body weight were analyzed to study the toxicity. LD50 determined using Reed and Munich formula. Vital organs average weight showed no difference between control group and treatment groups from the lowest dose until the highest dose. In addition, the body weight data showed no difference between control group and treatment groups. LD50 for Brucea javanica extract using Reed and Munich formula was 1003.65 mg/kg bw. The result of the study showed that extract were categorized as lightly toxic

Toxicological Evaluation of Tetrameles Nudiflora Methanolic Extract

Exploration of Mekongga national park resulted in novel finding of anticancer property from Tetrameles nudiflora. The investigation of toxic features of T. nudiflora is vital for further studies of its pharmacological activities. Acute toxicity test was done on methanolic extracts of T. nudiflora in DDY mice. Animals were divided into 5 groups: Group 1 was given 1 ml solution of 2.5% Tween 80 in a single oral dose; Group 2, 3, 4 and 5 were orally administrated a single dose of 1, 2, 4 and 8 g/kg body weight T. nudiflora, respectively. Toxic effects of the extract were evaluated on the basis of behavioral observations in the form of locomotor activity; curiosity; defecation; urination and also animal mortality. Observations were carried out for 14 days. No significant changes on body weight, and behavioural activities were recorded. Mortality was recorded up to 22% of the male group, and 11% within the female group. The T.nudiflora extracts tested for toxicity against brine shrimp had 50% lethal concentration (LC50) values of 46.67 μg/ml. It can be concluded that methanol extracts of T. nudiflora are potential to be explored as anticancer (LC50=46.67 μg/ml). The extract is slightly toxic in male mice with Lethal Dose 50 (LD50) 12.6 g/kg body weight, and practically non toxic for female (LD50>15 g/kg body weight)

Additional file 2 of Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Additional file 2. Email invitation

Additional file 7 of Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Additional file 7. Sensitivity analyses: various meta-analytic approaches